Controversies over the use of GnRH agonists for reduction of chemotherapy-induced gonadotoxicity

Keyphrases

• Gonadotropin-releasing Hormone 100%
• Gonadotoxicity 100%
• Chemotherapy-induced 100%
• Ovarian Function 100%
• Chemotherapy 75%
• Fertility Preservation 50%
• Quality of Life 25%
• Osteoporosis 25%
• Vasomotor Symptoms 25%
• Malignancy 25%
• Young Women 25%
• Remission 25%
• In Cancer 25%
• Premature Ovarian Failure 25%
• Agonistic 25%
• Ovarian Tissue Preservation 25%
• Infertility 25%
• Cancer Incidence 25%
• Cancer Outcomes 25%
• Adult Female Patients 25%
• Promising Treatment 25%
• Female Cancer 25%
• Highly Available 25%
• Iatrogenic Infertility 25%
• Embryo Cryopreservation 25%
• Ovarian Transposition 25%
• Co-treatment 25%
• Ovum 25%
• Young People 25%
• Cardiovascular Risk Factors 25%
• Reproductive Futures 25%
• Reproductive Quality 25%
• Young Female Cancer Patients 25%

Medicine and Dentistry

• Ovary Function 100%
• Gonadorelin Agonist 100%
• Chemotherapy 100%
• Gonadorelin 75%
• Malignant Neoplasm 50%
• Fertility Preservation 50%
• Osteoporosis 25%
• Quality of Life 25%
• Vasomotor 25%
• Cancer 25%
• Cardiovascular Disease 25%
• Cancer Therapy 25%
• Ovum 25%
• Cancer Incidence 25%
• Primary Ovarian Insufficiency 25%
• Cryopreservation 25%
• Treatment Outcome 25%
• Sexual Dysfunction 25%